RedChip Companies, Inc.

06/09/2026

📅 24 Hours Until RedChip's Future Tech Investor Conference — Here's What You'll Have Access To

On June 10 at 9:30 AM ET, RedChip's Future Tech Investor Conference goes live. Here's a look at the full lineup:

⏰ Full Schedule:
• 10:00 AM — ASP Isotopes (Nasdaq: ASPI) | CEO Paul Mann | Critical materials: isotopes for nuclear medicine, semiconductors & energy
• 10:30 AM — Abundia Global Impact Group (NYSE: AGIG) | CEO Ed Gillespie | Waste plastics & biomass → low-carbon fuels
• 11:00 AM — Everspin Technologies (Nasdaq: MRAM) | CEO Sanjeev Aggarwal + CFO Bill Cooper | MRAM persistent memory for AI, defense & data centers
• 11:30 AM — AINOS Inc. (Nasdaq: AIMD) | Jack Lu, Head of Corporate Development | AI-powered multi-disease detection
• 12:00 PM — Velo3D (Nasdaq: VELO) | CEO Arun Jeldi + CFO Jim Suva | Metal 3D printing for aerospace & defense
• 12:30 PM — LanzaTech Global (Nasdaq: LNZA) | CEO Dr. Jennifer Holmgren | Carbon recycling → SAF & specialty chemicals
• 1:00 PM — Skyline Builders Group (Nasdaq: SKBL) | Executive Chairman Paul Mann | Construction technology
• 1:30 PM — RanMarine (Private) | Co-Founders Richard Hardiman + Mike Foss | Autonomous maritime vessels
• 1:45 PM — SubSea (Private) | CEO Dustin Whitehead | Underwater technology
• 2:00 PM — Hi Solutions (Private) | CEO John Parker | AI platform
• 2:30 PM — Eco Wave Power Global (Nasdaq: WAVE) | CEO Inna Braverman | Wave-to-electricity technology
• 3:00 PM — BIO-key International (OTC: BKYI) | CEO Mike DePasquale | Biometric IAM
• 3:30 PM — Syntec Optics (Nasdaq: OPTX) | Chairman & CEO Al Kapoor | Precision optics for defense, space & AI

Free. Virtual. Live Q&A with every presenter.

If you haven't registered yet: https://redchip.news/3RfnDbf

06/09/2026

🔬 BioVie (Nasdaq: $BIVI) is approaching two imminent clinical readouts — and CEO Cuong Do explains exactly what's at stake.

In our exclusive interview, Do breaks down the Parkinson's trial, now in study closeout following completion of its patient-facing portion, and the Long COVID trial, which just enrolled its last patient at Yale. Both are on pace to read out by end of summer or early fall.

Bezisterim has the potential to be the first new Parkinson's therapy in five decades — and the first therapy for Long COVID. The company currently holds approximately 2x its market cap in cash, with runway well beyond the readouts.

🔗 Watch the full interview: https://redchip.news/4uFTX5Z

FierceBiotech Genetic Engineering & Biotechnology News PharmaVoice

CEO Cuong Do joins RedChip to discuss BioVie (Nasdaq: BIVI), a clin...

06/09/2026

⏰ Tomorrow: RedChip's Future Tech Investor Conference + Live Q&A with 13 Company Executives

Tomorrow, June 10 at 9:30 AM ET, RedChip's Future Tech Investor Conference goes live — and the opportunity to hear directly from the management teams shaping AI, automation, advanced manufacturing, and digital infrastructure doesn't get more direct than this.

From Everspin's expanding MRAM manufacturing footprint — now backed by a new $40M U.S. defense contract — to Velo3D's metal 3D printing solutions trusted by SpaceX and Honeywell, to LanzaTech's carbon transformation technology, tomorrow's lineup represents a cross-section of the tech economy that most investors never get direct access to.

Every session includes a live Q&A. You can ask the questions that matter to you — directly to the CEO.

📊 A few sessions worth circling on the schedule:
10:00 AM ET — ASP Isotopes (NASDAQ: ASPI) | CEO Paul Mann
11:00 AM ET — Everspin Technologies (NASDAQ: MRAM) | CEO Sanjeev Aggarwal & CFO Bill Cooper
12:00 PM ET — Velo3D (NASDAQ: VELO) | CEO Arun Jeldi & CFO Jim Suva
12:30 PM ET — LanzaTech (NASDAQ: LNZA) | CEO Dr. Jennifer Holmgren
2:30 PM ET — Eco Wave Power (Nasdaq: WAVE) | CEO Inna Braverman
3:30 PM ET — Syntec Optics (Nasdaq: OPTX) | CEO Al Kapoor

Registration is still open — don't miss your chance to get in.

🔗 Click the link in the comments to register.

06/09/2026

🧠 Lantern Pharma (NASDAQ: LTRN): withZeta.ai Positions AI at the Center of Cancer Drug Discovery
90% of new drug discoveries fail in the clinic — costing billions of dollars and decades of lost time.

At Nasdaq MarketSite in New York City, Lantern Pharma unveiled withZeta.ai — the company’s multi-agentic AI co-scientist platform designed for oncology research and precision drug development.

The announcement is notable for investors because withZeta.ai is built to reason across clinical trials, scientific literature, molecular databases, and biomarker data simultaneously — spanning 438 cancer types and compressing years of research into hours.

🔬 Key platform differentiators highlighted:
• Multi-agentic AI architecture designed to think alongside researchers
• Cross-analysis of oncology datasets, trials, and scientific literature
• Proprietary AI infrastructure developed over more than a decade
• Focus on cancers with limited treatment options and high unmet need

For investors, the key takeaway is Lantern Pharma’s positioning at the intersection of artificial intelligence and precision oncology, pairing its clinical-stage oncology pipeline with a differentiated AI-driven discovery platform.

LTRN is a client of RedChip. To learn more, click the link in the comments.

FierceBiotech Genetic Engineering & Biotechnology News PharmaVoicearmaVoice

06/09/2026

🧠 Nexalin Technology $NXL: Drug-Free Brain Stimulation Platform Pivots From R&D to Revenue — With 7 Catalysts Lined Up Through 2027

Nexalin's proprietary DIFS™ technology delivers 15 milliamps of deep intracranial frequency stimulation — targeting the midbrain structures where trauma and mental health disorders actually originate. Competing approaches top out at 1 milliamp, limiting pe*******on to the cortical surface. That gap is the core of the investment thesis.

💡 Why Investors Should Be Watching:
- Gen-3 HALO™ Clarity headset now off the manufacturing line and entering clinical distribution
- New device cleared in China; distribution targeted Q3–Q4 2026
- Alzheimer's dementia data release targeted Q4 2026
- Health and wellness consumer product line in development — no FDA clearance required
- No debt, no warrants on the balance sheet

The mental health market is projected to reach $537 billion by 2030. $NXL is building a recurring revenue, subscription-based platform to compete for a share of it — drug-free.

👉 To learn more about $NXL and to read our full disclosure, visit: https://www.NXLinfo.com

FierceBiotech Genetic Engineering & Biotechnology News PharmaVoice

06/09/2026

Top scientists and Pfizer’s former CMO are backing Calidi Biotherapeutics (New York Stock Exchange American: CLDI).

Why? Because its systemic genetic delivery platform could redefine how we treat cancer.

🎥 Watch our 30-sec investor overview.
🔗 https://redchip.news/4nLmPXR

Northwestern University City of Hope The Lancet PharmaVoice Genetic Engineering & Biotechnology News

Why are top biotech leaders — including Pfizer’s former Chief Medical Officer — joining forces with a small-cap company like Calidi Biotherapeutics (NYSE Ame...

06/08/2026

⏰ One Week Away: New Horizon Aircraft (Nasdaq: HOVR) RedChip Investor Webinar — June 15 at 4:15 PM ET

One week from today, New Horizon Aircraft management goes live with RedChip investors to walk through the Cavorite X7 platform, the commercialization roadmap, and why HOVR is building a differentiated position in a market where most competitors are still constrained by battery limitations and short-range urban air taxi economics.

🛩️ Why the investment thesis is building:
- Hybrid-electric propulsion system sidesteps the core limitations of battery-only eVTOL platforms that continue to challenge first-generation competitors
- Payload capacity of ~1,500 lbs significantly exceeds many competing eVTOL platforms, opening mission-critical use cases in medevac, organ transport, military logistics, and disaster response
- Expected unit pricing of ~$6–8M per aircraft vs. $12–15M for comparable helicopters
- Early commercial interest demonstrated through LOIs, including JetSetGo for up to 50 aircraft, with a full-scale aircraft under construction and flight testing targeted for 2027

If you haven't registered yet, now is the time — join management live next Sunday for the HOVR investor webinar.

🔗 Register here: https://redchip.news/3PfXE2V

RedChip's comprehensive IR platform is the ideal solution for small- and mid-cap companies who want to increase their retail and institutional shareholder base.

06/08/2026

📣 New Horizon Aircraft (Nasdaq: HOVR) Investor Webinar | June 15, 2026 | 4:15 PM ET — Mark Your Calendar

The advanced air mobility market is projected to reach ~$1 trillion, and New Horizon Aircraft is building what may be the most capable eVTOL platform in it. Mark your calendar for June 15 at 4:15 PM ET and hear the full investment case directly from management.

✈️ Why aerospace investors are watching:
- Patented fan-in-wing architecture protected by 30+ patents
- Target performance of ~250 mph speed and ~500-mile range
- Operating economics of ~$0.97 per seat mile vs. ~$4–$6 for comparable helicopters - LOI from JetSetGo for up to 50 aircraft demonstrates early commercial validation

Register now to secure your spot at this exclusive RedChip virtual investor webinar.

🔗 Register here: https://redchip.news/3PfXE2V

Hangar X Studios Aviation International News Breaking Defense Royal Aeronautical Society Top Aces

06/08/2026

⚛️ ASP Isotopes (Nasdaq: ASPI) CEO Paul Mann: Commercial isotope ramp, Silicon 28 validation, and the 2026 inflection setup

Watch our exclusive interview with ASP Isotopes' CEO Paul Mann covering what investors should be watching as ASPI moves from buildout to commercialization.

💡 ASPI is leveraged to several high priority markets spanning nuclear medicine, semiconductors, helium, and nuclear fuels, with the near-term opportunity centered on turning validated products into sustained commercial deliveries that can support cash generation and scale.

🔗 Watch our full interview: https://redchip.news/4qDuze8

World Nuclear News S&P Global Energy Nuclear Energy Institute